LIB Therapeutics Signs an Agreement with Hasten Biopharmaceutical to Develop and Commercialize Lerodalcibep in Greater China
Shots:
- LIB will receive $20M up front, `$305M upon achievement of clinical, regulatory & commercial milestones along with royalties on net sales in Greater China
- Hasten gets an exclusive right to develop & commercialize lerodalcibep (PCSK9 inhibitor) in Greater China (Chinese Mainland, Hong Kong, Macau & Taiwan). The P-III trial (LIBerate-HeFH) results of lerodalcibep for He-FH who are very high or high-risk for CVD presented at ESC 2023
- Hasten plans to submit an IND application to NMPA in Q4’23 and initiate the P-III trials for hypercholesterolemia in Greater China along with planning to launch lerodalcibep in China shortly. LIB is expected to submit a BLA to the US FDA in Q1’24 & MAA to the EMA in Q2’24
Ref: Businesswire | Image: LIB Therapeutics
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
